[go: up one dir, main page]

MX2025004670A - Metodos para tratar colestasis intrahepatica familiar progresiva - Google Patents

Metodos para tratar colestasis intrahepatica familiar progresiva

Info

Publication number
MX2025004670A
MX2025004670A MX2025004670A MX2025004670A MX2025004670A MX 2025004670 A MX2025004670 A MX 2025004670A MX 2025004670 A MX2025004670 A MX 2025004670A MX 2025004670 A MX2025004670 A MX 2025004670A MX 2025004670 A MX2025004670 A MX 2025004670A
Authority
MX
Mexico
Prior art keywords
methods
intrahepatic cholestasis
progressive familial
familial intrahepatic
treating progressive
Prior art date
Application number
MX2025004670A
Other languages
English (en)
Inventor
Thomas Jaecklin
Original Assignee
Mirum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirum Pharmaceuticals Inc filed Critical Mirum Pharmaceuticals Inc
Publication of MX2025004670A publication Critical patent/MX2025004670A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91188—Transferases (2.) transferring nitrogenous groups (2.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se proporcionan métodos para tratar colestasis en un sujeto que tiene enfermedad hepática. Más específicamente, la presente invención se refiere a métodos para tratar colestasis intrahepática familiar progresiva (PFIC) en un sujeto donde el método incluye administrar maralixibat a un sujeto en necesidad del mismo.
MX2025004670A 2022-10-23 2025-04-22 Metodos para tratar colestasis intrahepatica familiar progresiva MX2025004670A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263418589P 2022-10-23 2022-10-23
US202263423310P 2022-11-07 2022-11-07
US202363471291P 2023-06-06 2023-06-06
US202363522355P 2023-06-21 2023-06-21
PCT/US2023/035697 WO2024091445A1 (en) 2022-10-23 2023-10-23 Methods for treating progressive familial intrahepatic cholestasis

Publications (1)

Publication Number Publication Date
MX2025004670A true MX2025004670A (es) 2025-07-01

Family

ID=90831657

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025004670A MX2025004670A (es) 2022-10-23 2025-04-22 Metodos para tratar colestasis intrahepatica familiar progresiva

Country Status (11)

Country Link
US (1) US20240173317A1 (es)
EP (1) EP4604959A1 (es)
JP (1) JP2025535313A (es)
KR (1) KR20250093383A (es)
CN (1) CN120091821A (es)
AU (1) AU2023366174A1 (es)
CA (1) CA3268104A1 (es)
IL (1) IL319672A (es)
MX (1) MX2025004670A (es)
TW (1) TW202428276A (es)
WO (1) WO2024091445A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021015815A2 (pt) * 2019-02-12 2022-01-18 Mirum Pharmaceuticals Inc Métodos para tratar colestase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014010228B1 (pt) * 2011-10-28 2020-09-29 Lumena Pharmaceuticals Llc Uso de inibidores de reciclagem de ácido biliar para o tratamento de hipercolemia e doença hepática colestática
BR112021015815A2 (pt) * 2019-02-12 2022-01-18 Mirum Pharmaceuticals Inc Métodos para tratar colestase

Also Published As

Publication number Publication date
TW202428276A (zh) 2024-07-16
AU2023366174A1 (en) 2025-04-03
IL319672A (en) 2025-05-01
EP4604959A1 (en) 2025-08-27
KR20250093383A (ko) 2025-06-24
CA3268104A1 (en) 2024-05-02
JP2025535313A (ja) 2025-10-24
US20240173317A1 (en) 2024-05-30
CN120091821A (zh) 2025-06-03
WO2024091445A1 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
EP4245367A3 (en) Methods for treating cholestasis
MX2025004670A (es) Metodos para tratar colestasis intrahepatica familiar progresiva
EA200970237A1 (ru) Применение тенектеплазы для лечения острого ишемического инсульта
CO2021011034A2 (es) Métodos para tratar el mieloma múltiple
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
GB0109146D0 (en) Treatment of type 2 diabetes
MX2023004399A (es) Tratamiento de combinacion.
EA201891388A1 (ru) Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека
PH12020552212A1 (en) Compositions and methods for the treatment of hemoglobinopathies and thalassemias
MX2022006533A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo.
TN2022000113A1 (en) Dosing regimen for anti-dll3 agents
NO20044564L (no) Fremgangsmater for behandling av nekrotiserende enterocolit
ZA202200906B (en) Anti-her2/anti-4-1bb bispecific antibody and use thereof
AR054525A1 (es) Composiciones y metodos para eltratamiento de sintomas relacionados con el ciclo
WO2020047352A8 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
PL1694354T3 (pl) Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
ZA202200905B (en) Anti-egfr/anti-4-1bb bispecific antibody and use thereof
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
TW200507840A (en) Method of treating multiple myeloma
MX2022015959A (es) Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
CO2022006367A2 (es) Tratamiento génico para la enfermedad de alzheimer
MX2023006669A (es) Anticuerpo biespecifico para alfa sinucleina (a-syn)/receptor de factor 1 de crecimiento tipo insulina (igf1r) y uso del mismo.
WO2007056540A3 (en) Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
PH12022550698A1 (en) Treatment of alcoholic hepatitis